Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

37.14
-0.3550-0.95%
Volume:181.74K
Turnover:6.74M
Market Cap:3.50B
PE:-6.32
High:37.90
Open:37.22
Low:36.36
Close:37.49
Loading ...

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (Bla) for Ux111 Aav Gene Therapy to Treat Sanfilippo Syndrome Type a (Mps Iiia)

THOMSON REUTERS
·
18 Feb

Ultragenyx Pharmaceutical Inc - FDA Grants Priority Review for Ultragenyx Bla With Pdufa Date Aug 18, 2025

THOMSON REUTERS
·
18 Feb

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

GlobeNewswire
·
18 Feb

Ultragenyx Pharmaceutical: Strong Growth Prospects and Pipeline Advancements Reinforce Buy Rating

TIPRANKS
·
17 Feb

Evercore ISI Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
17 Feb

Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call

Thomson Reuters StreetEvents
·
14 Feb

Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y

Zacks
·
14 Feb

Wedbush Sticks to Their Hold Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
14 Feb

Morgan Stanley Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
14 Feb

Ultragenyx Pharma Price Target Maintained With a $95.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Feb

Promising Developments in Ultragenyx Pharmaceuticals Drive Ed Arce’s Buy Rating

TIPRANKS
·
14 Feb

Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

GuruFocus.com
·
14 Feb

U.S. RESEARCH ROUNDUP-Airbnb, CVS Health, Roku

Reuters
·
14 Feb

Ultragenyx Pharmaceutical’s Strong Sales and Promising Pipeline Support Buy Rating

TIPRANKS
·
14 Feb

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
14 Feb

Ultragenyx Pharmaceutical Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Feb

Ultragenyx Pharmaceutical Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
14 Feb

Ultragenyx: Q4 Earnings Snapshot

Associated Press Finance
·
14 Feb

Ultragenyx Pharmaceutical Inc - 2025 Financial Guidance: Total Revenue Between $640 Million to $670 Million

THOMSON REUTERS
·
14 Feb

Ultragenyx Pharmaceutical Q4 2024 GAAP EPS $(1.39) Misses $(1.29) Estimate, Sales $164.877 Miss $155.393M Estimate

Benzinga
·
14 Feb